Cologuard® Included as Alternative Screening Test under Draft USPSTF Guidelines

Whitney Tilson Says Exact Sciences (EXAS) Still a Great Short

Hedge fund manager Whitney Tilson said Exact Sciences (NASDAQ: EXAS) is a great short at $10. Link

Mizuho Securities Cuts Price Target on Exact Sciences (EXAS) to $12 Following USPSTF Cologuard Guidelines

Mizuho Securities maintained a Buy rating on Exact Sciences (NASDAQ: EXAS), and cut the price target on price target to $12.00 (from $35.00), after USPSTF Cologuard guidelines have hampered visibility and added risk. Cologuard was only listed as an alternative colorectal screening test for the average-risk... More

Exact Sciences (EXAS) PT Lowered to $15 at Roth Capital, Recommends Buying on Weakness

Roth Capital analyst Chris Lewis lowered his price target on Exact Sciences (NASDAQ: EXAS) to $15.00 (from $31.00) after the USPSTF draft recommendation has designated Cologuard as an alternative rather than recommended test. The firm maintained a Buy rating ad is telling clients to buy on... More

Canaccord Genuity Reiterates Buy on Exact Sciences (EXAS) Following USPSTF's Draft Recommendation for Colorectal Screening Guidelines

Canaccord Genuity reiterated a Buy rating and $26.00 price target on Exact Sciences (NASDAQ: EXAS) following USPSTF's draft recommendation for colorectal screening guidelines. the report surprisingly did not include Cologuard as an "A" or "B" rated test, though it did mention it as an "alternative screening test" which EXAS interprets as being included in the... More

Benchmark Downgrades Exact Sciences (EXAS) to Hold

Benchmark downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Hold.

For an analyst ratings summary and ratings history on Exact Sciences click here. For more ratings news on Exact Sciences click here.

Shares of Exact Sciences closed at $18.53 yesterday.

USPSTF Draft Recommendation Not as Bullish as Expected for Exact Sciences (EXAS), Wedbush Says; But Would Buy Below $18

Wedbush analyst Zarak Khurshid weighed in on Exact Sciences (NASDAQ: EXAS) following the USPSTF draft recommendation which was not as bullish as the Street was expecting. That said the firm would be buyers below their $18 price target.

Khurshid commented, "Yesterday, the United States Preventative Services Task Force (USPSTF) issued its draft recommendation on colorectal cancer screening which represents the first comprehensive update since... More

Impact on Exact Sciences (EXAS) from USPSTF Guidlines 'Unclear', Jefferies Says; Would Be Buyers on Weakness

Jefferies analyst Brandon Couillard weighed in on Exact Sciences (NASDAQ: EXAS) after USPSTF's draft colorectal cancer screening guidelines, which he is calling "unclear." That said, he believes the sell-off in the stock is overdone and would be a buyer on the... More

Exact Sciences (EXAS) Issues Statement on USPSTF Colorectal Cancer Screening Draft Recommendation

After plunging in after-hours trading Monday, Exact Sciences (NASDAQ: EXAS) issued the following statement following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.

USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines... More

Exact Sciences (EXAS) Pleased Cologuard Included in USPSTF Draft Colorectal Cancer Screening Guidelines

Exact Sciences (Nasdaq: EXAS) issued the following statement today following the U.S. Preventive Services Task Force (USPSTF) draft recommendation statement for colorectal cancer screening.

USPSTF included Cologuard in the draft guidelines as an alternative screening test, along with CT colonography. The draft guidelines recommend an A rating for... More